Disclosure Plus

KESPION Decides on 13 Billion Won Third-Party Private Placement

Shin Ha-yeon
2026-08-18 15:05:19
[Edaily Reporter Shin Ha-yeon ] KESPION(079190)announced on the 18th that it has decided to conduct a third-party private placement worth approximately 13 billion won to raise operating funds.

Accordingly, 10,752,688 common shares will be issued at a price of 1,209 won per share, raising a total of 12.9999 billion won. The entire amount raised will be used as working capital. The payment date is September 14, and the new shares are scheduled to be listed on September 30.

The third-party allottee is the “Blue Materials, Parts, and Equipment New Technology Investment Fund No. 3.” The company stated that once the payment for this rights offering is completed, the investment fund will secure the position of largest shareholder. The newly issued shares will be subject to a one-year lock-up period.

Regarding the purpose of this capital increase, the company explained, “It is intended to achieve the company’s business objectives, such as maintaining its listing status and raising operating capital.”

Economy

Corporation

IT·Science

Economy

“Disappointing Remarks on Cryptocurrency by Yoo Si-min and Lee Jun-seok… It’s Time to Change Our Perception”

As the government’s draft of the Framework Act on Digital Assets—a key national policy initiative—is set to be submitted to the National Assembly shortly, some have pointed out that the negative perce…
2026-11-20 13:41:08

Corporation

curacle co., ltd. Files for U.S. Phase 2b Clinical Trial of CU06, an Oral Treatment for Diabetic Macular Edema

curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
2026-11-20 13:02:02

IT·Science

Aimed Bio Inc.’s ADC Technology Export Shows 60% Response Rate in Phase 1 Clinical Trial… Moving Forward with U.S. Approval Trials

#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…
2026-11-20 13:07:02